LRRK2 kinase and GRPase inhibitors, such as MLi-2, PF-06447475, GNE-0877, compound 68 and 70, and FX2149, initially developed for treatment of Parkinson’ disease [79], could be repurposed to treat LRRK2-associated lung cancer. Here, LRRK2 is linked to lung carcinoma.